Cyclerion Therapeutics, Inc.
NASDAQ: CYCN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Regina Graul
- Employees
- 1
- Headquarters
- Cambridge, United States
- IPO year
- 2019
- Market cap
- $13.6M
- Website
- https://www.cyclerion.com
Loading CYCN…
Loading profile data…Frequently asked questions about CYCN
What does Cyclerion Therapeutics, Inc. (CYCN) do?
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator desi...
Where does CYCN trade?
Cyclerion Therapeutics, Inc. (CYCN) trades on the NASDAQ Global Select.
What sector is CYCN in?
Cyclerion Therapeutics, Inc. (CYCN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cyclerion Therapeutics, Inc.?
Regina Graul is the chief executive officer of Cyclerion Therapeutics, Inc. (CYCN).
Where is Cyclerion Therapeutics, Inc. headquartered?
Cyclerion Therapeutics, Inc. is headquartered in United States.
Does CYCN pay a dividend?
Cyclerion Therapeutics, Inc. (CYCN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYCN go public?
Cyclerion Therapeutics, Inc. (CYCN) completed its initial public offering in 2019.